Publication

EHA •
15 June, 2025 •
•

Real-world effectiveness of pacritinib in patients with myelofibrosis who have thrombocytopenia and anemia

Raajit Rampal, Samantha Eiffert, Michael Marrone, Lisa Morere, Abiola Oladapo, Anubhav Sharma, Purvi Suthar, Anupama Vasudevan, Michael Vredenburg , John Mascarenhas

Available materials

Poster

Publication

EHA •
15 June, 2025 •
•

Real-World Treatment Patterns and Clinical Outcomes in Patients with Myelofibrosis Treated with Pacritinib (PAC) with platelets ≥50 x10^9/L at PAC initiation: Interim results from the MY-PAC Study

Doug Tremblay, Abiola Oladapo, Emily Levine, Michael Marrone, Djibril Liassou, Purvi Suthar, Adina Geprifti, Gerard Hoehn, Michael Vredenburg , Bruce Feinberg, Naveen Pemmaraju, James Rossetti

Available materials

Poster

Symposium

EHA •
14 June, 2025 •
•

Boosting Platelets: Expert Approaches to Adult Immune Thrombocytopenia (ITP)

Monica Carpenedo, María Luisa Lozano, Waleed Ghanima

Available materials

Slides Video

Publication

Economic Burden of Cytopenia in Patients with Myelofibrosis: Analysis of a US National Administrative Claims Database

Real-world effectiveness of pacritinib in patients with myelofibrosis who have thrombocytopenia and anemia

Real-World Treatment Patterns and Clinical Outcomes in Patients with Myelofibrosis Treated with Pacritinib (PAC) with platelets ≥50 x10^9/L at PAC initiation: Interim results from the MY-PAC Study

Boosting Platelets: Expert Approaches to Adult Immune Thrombocytopenia (ITP)

Hematologic response in patients with myelofibrosis treated with pacritinib in real-word clinical settings

Cytopenia is associated with real-world disease progression and diminished survival in patients with myelofibrosis: Analysis of a US national administrative claims database

Real-world treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib previously treated with ruxolitinib

Putting on your VEXAS goggles: Seeing what’s in plain sight

Economic Burden of Cytopenia in Patients with Myelofibrosis: Analysis of a US National Administrative Claims Database

Real-world effectiveness of pacritinib in patients with myelofibrosis who have thrombocytopenia and anemia

Real-World Treatment Patterns and Clinical Outcomes in Patients with Myelofibrosis Treated with Pacritinib (PAC) with platelets ≥50 x10^9/L at PAC initiation: Interim results from the MY-PAC Study

Boosting Platelets: Expert Approaches to Adult Immune Thrombocytopenia (ITP)

Hematologic response in patients with myelofibrosis treated with pacritinib in real-word clinical settings

Cytopenia is associated with real-world disease progression and diminished survival in patients with myelofibrosis: Analysis of a US national administrative claims database

Real-world treatment patterns and outcomes in patients with myelofibrosis treated with pacritinib previously treated with ruxolitinib

Putting on your VEXAS goggles: Seeing what’s in plain sight​

Putting on your VEXAS goggles: Seeing what’s in plain sight